Revenue growth and margin expansion are accelerating, with FY26 guidance maintained. Key catalysts ahead include sBLA submission for lifileucel in mNSCLC in 2027 and potential UK/Switzerland approvals in 1Q27. Monitor enrollment updates in the SARATOGA and TILVANCE-301 registrational trials.
Drugs in focus
IOVA drug pipeline →Amtagvi
● Neutral Named in this 8-K- Impact
- Phase
- Approved (accelerated approval)
- Time to market
- Already approved and marketed (FDA accelerated approval Feb 16, 2024). Confirmatory Phase 3 (TILVANCE-301) is ongoing to convert to full approval.
- Next catalyst
- BLA filing · 2027
What to watchWatch for TILVANCE-301 Phase 3 interim or topline results (undated but the key catalyst for converting accelerated to full approval and expanding into frontline) and quarterly revenue growth trajectory, Q2 2026 guidance is $86M-$88M. Also monitor IOV-LUN-202 NSCLC registrational data (Fast Track, potential launch 2H27). At ~$3.97 with a mean analyst target of $8.80 (177% upside), the stock prices in meaningful commercial execution but not a TILVANCE-301 success.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $7.74entry
- T+1 · 11d ago +3.88%α +3.56% · $8.04
- T+5 · 5d ago −1.42%α −4.71% · $7.63
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Iovance Biotherapeutics reported record Q3 2026 revenue of ~$122M, up ~80% YoY, with gross margin improving to ~60%. The company maintained its FY26 revenue guidance of $410M-$420M and highlighted positive clinical data in NSCLC and sarcoma. Cash position of ~$382M is expected to fund operations well into 2029.
Key Financial Metrics
Key Facts
- Q3 2026 total product revenue of ~$122M, up ~80% from ~$67M in Q3 2025 and ~22% from ~$99M in Q2 2026
- U.S. Amtagvi revenue of ~$102M, up ~77% YoY and ~12% sequentially
- Gross margin of ~60%, up from 56% in Q2 2026
- R&D expenses decreased ~16% sequentially, marking fifth straight quarter of improvement
- FY26 revenue guidance maintained at $410M-$420M
- Cash position of ~$382M as of September 30, 2026, expected to fund operations well into 2029
- 24.6% ORR in 69 patients with non-squamous mNSCLC in IOV-LUN-202 trial; 59.1% ORR in biomarker-selected subgroup
- 55.6% confirmed ORR in UPS and DDLPS in SARATOGA trial
- Net loss narrowed to $22.3M from $91.3M in Q3 2025
Financial Impact
Record quarterly revenue of ~$122M, 80% YoY growth; gross margin expanded to ~60%; operating loss narrowed to ~$24M from ~$95M in Q3 2025
Risk Factors
- Company remains pre-profitability with net loss of $22.3M in Q3 2026
- Dependence on continued Amtagvi commercial adoption and ATC network expansion
- Clinical and regulatory risks for pipeline programs in NSCLC, sarcoma, and endometrial cancer
- Potential dilution from equity financing needs if cash runway extends beyond current projections
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-123030 |
| Document: tm2628901d1_8k.htm | 0001104659-26-123030 |
| Document: 0001104659-26-123030-index-headers.html | 0001104659-26-123030 |
| Document: 0001104659-26-123030-index.html | 0001104659-26-123030 |
| Document: 0001104659-26-123030.txt | 0001104659-26-123030 |
| 8-K Data (Synthetic) | 0001104659-26-123030 |
Track record
21 reports on IOVA
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
- Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $7.74 Now $7.55 −2.45% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
- Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
- Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers